Physicians' Academy for Cardiovascular Education

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - Imperial College London, UK

Video navigation menu

  • Available interventions that reduce CVD 0:47
  • The role of BET inhibition in the development of CVD 3:10
  • Observed reduction in CVD events with apabetalone 4:38
  • Aim and study design of BETonMACE 7:36

Educational information

This lecture was part of a CME accredited symposium: "LDL-c: Done Deal, Next Epigenetics?" during ESC 2018 in Munich, Germany.

Faculty

Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Resverlogix.

View slides of prof. Ray

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: